Standard Chem & Pharm CO., LTD. (1720.TW)
TWD 57.2
(0.17%)
TWD 57.2
(0.17%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.08 Billion TWD | -40.92% |
| 2022 | 2.24 Billion TWD | 14.1% |
| 2021 | 1.96 Billion TWD | 94.43% |
| 2020 | 1.01 Billion TWD | -20.8% |
| 2019 | 1.27 Billion TWD | 5.01% |
| 2018 | 1.21 Billion TWD | 5.99% |
| 2017 | 1.14 Billion TWD | 36.62% |
| 2016 | 841.23 Million TWD | 13.43% |
| 2015 | 741.62 Million TWD | 14.61% |
| 2014 | 647.08 Million TWD | -3.46% |
| 2013 | 670.28 Million TWD | -0.75% |
| 2012 | 675.35 Million TWD | 14.87% |
| 2011 | 587.95 Million TWD | -32.95% |
| 2010 | 876.89 Million TWD | 62.14% |
| 2009 | 540.82 Million TWD | 140.77% |
| 2008 | 224.62 Million TWD | 17.42% |
| 2007 | 191.29 Million TWD | -48.29% |
| 2006 | 369.9 Million TWD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 1.48 Billion TWD | -12.6% |
| 2024 Q2 | 1.17 Billion TWD | -21.24% |
| 2023 Q4 | 1.7 Billion TWD | -12.39% |
| 2023 FY | 1.7 Billion TWD | -24.29% |
| 2023 Q1 | 2.09 Billion TWD | -6.76% |
| 2023 Q2 | 1.85 Billion TWD | -11.26% |
| 2023 Q3 | 1.94 Billion TWD | 4.43% |
| 2022 Q2 | 2.07 Billion TWD | 16.08% |
| 2022 FY | 2.24 Billion TWD | 14.1% |
| 2022 Q4 | 2.24 Billion TWD | -19.49% |
| 2022 Q3 | 2.79 Billion TWD | 34.31% |
| 2022 Q1 | 1.79 Billion TWD | -9.1% |
| 2021 Q1 | 987.12 Million TWD | -2.57% |
| 2021 FY | 1.96 Billion TWD | 94.43% |
| 2021 Q3 | 1.18 Billion TWD | 22.13% |
| 2021 Q4 | 1.96 Billion TWD | 65.62% |
| 2021 Q2 | 973.85 Million TWD | -1.34% |
| 2020 Q3 | 1.17 Billion TWD | 22.67% |
| 2020 FY | 1.01 Billion TWD | -20.8% |
| 2020 Q1 | 1.27 Billion TWD | -0.7% |
| 2020 Q4 | 1.01 Billion TWD | -13.92% |
| 2020 Q2 | 959.45 Million TWD | -24.47% |
| 2019 Q4 | 1.27 Billion TWD | -19.6% |
| 2019 FY | 1.27 Billion TWD | 5.01% |
| 2019 Q3 | 1.59 Billion TWD | 39.71% |
| 2019 Q2 | 1.13 Billion TWD | -15.87% |
| 2019 Q1 | 1.35 Billion TWD | 11.12% |
| 2018 FY | 1.21 Billion TWD | 5.99% |
| 2018 Q4 | 1.21 Billion TWD | 3.39% |
| 2018 Q3 | 1.17 Billion TWD | 1.96% |
| 2018 Q2 | 1.15 Billion TWD | 7.88% |
| 2018 Q1 | 1.07 Billion TWD | -6.8% |
| 2017 Q2 | 979.2 Million TWD | 0.67% |
| 2017 Q4 | 1.14 Billion TWD | -0.64% |
| 2017 FY | 1.14 Billion TWD | 36.62% |
| 2017 Q3 | 1.15 Billion TWD | 18.12% |
| 2017 Q1 | 972.68 Million TWD | 15.63% |
| 2016 FY | 841.23 Million TWD | 13.43% |
| 2016 Q2 | 493.02 Million TWD | -25.09% |
| 2016 Q3 | 802.78 Million TWD | 62.83% |
| 2016 Q4 | 841.23 Million TWD | 4.79% |
| 2016 Q1 | 658.11 Million TWD | -11.26% |
| 2015 Q1 | 613.25 Million TWD | -5.23% |
| 2015 Q4 | 741.62 Million TWD | 22.27% |
| 2015 FY | 741.62 Million TWD | 14.61% |
| 2015 Q3 | 606.56 Million TWD | 10.59% |
| 2015 Q2 | 548.46 Million TWD | -10.57% |
| 2014 FY | 647.08 Million TWD | -3.46% |
| 2014 Q4 | 647.08 Million TWD | -23.17% |
| 2014 Q3 | 842.28 Million TWD | 31.53% |
| 2014 Q2 | 640.39 Million TWD | 0.64% |
| 2014 Q1 | 636.34 Million TWD | -5.06% |
| 2013 Q2 | 393.93 Million TWD | -21.94% |
| 2013 Q1 | 504.67 Million TWD | -25.27% |
| 2013 FY | 670.28 Million TWD | -0.75% |
| 2013 Q3 | 476.44 Million TWD | 20.94% |
| 2013 Q4 | 670.28 Million TWD | 40.69% |
| 2012 Q3 | 495.29 Million TWD | -1.17% |
| 2012 Q1 | 494.22 Million TWD | -15.94% |
| 2012 FY | 675.35 Million TWD | 14.87% |
| 2012 Q4 | 675.35 Million TWD | 36.35% |
| 2012 Q2 | 501.13 Million TWD | 1.4% |
| 2011 Q1 | 878.78 Million TWD | 0.22% |
| 2011 Q4 | 587.95 Million TWD | -6.85% |
| 2011 Q3 | 631.17 Million TWD | -29.68% |
| 2011 Q2 | 897.6 Million TWD | 2.14% |
| 2011 FY | 587.95 Million TWD | -32.95% |
| 2010 FY | 876.89 Million TWD | 62.14% |
| 2010 Q4 | 876.89 Million TWD | 0.0% |
| 2009 FY | 540.82 Million TWD | 140.77% |
| 2008 FY | 224.62 Million TWD | 17.42% |
| 2007 FY | 191.29 Million TWD | -48.29% |
| 2006 FY | 369.9 Million TWD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Grape King Bio Ltd | 192.92 Million TWD | -460.854% |
| Maywufa Company Ltd. | 442.66 Million TWD | -144.428% |
| ScinoPharm Taiwan, Ltd. | 621.1 Million TWD | -74.206% |
| Lotus Pharmaceutical Co., Ltd. | 11.58 Billion TWD | 90.66% |
| LIWANLI Innovation Co., Ltd. | 2.63 Million TWD | -40947.041% |
| YungShin Global Holding Corporation | 1.23 Billion TWD | 12.701% |
| PhytoHealth Corporation | 28.11 Million TWD | -3748.479% |
| SCI Pharmtech, Inc. | 1.04 Billion TWD | -3.792% |
| Formosa Laboratories, Inc. | 4.06 Billion TWD | 73.379% |
| PharmaEssentia Corporation | 1.2 Billion TWD | 9.85% |
| Bora Pharmaceuticals Co., LTD. | 5 Billion TWD | 78.403% |